IV BCV for Adenovirus Infections

(ATHENA Trial)

Recruiting at 13 trial locations

Overseen By Rochelle Maher

Age: Any Age

Sex: Any

Trial Phase: Phase 2

Sponsor: SymBio Pharmaceuticals

Disqualifiers: Weight ≥120 kg, Grade 2+ diarrhea, Stage 4 skin GVHD, Stage 2+ liver GVHD, Stage 2+ gut GVHD

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 1 Jurisdiction This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 8

Duration: 4 weeks

52 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinator or your doctor for guidance.

What data supports the effectiveness of the drug Brincidofovir for treating adenovirus infections?

Research shows that Brincidofovir, a drug related to cidofovir, has been effective in treating severe adenovirus infections in patients with weakened immune systems, such as those who have had organ transplants. It is taken orally and has been shown to reduce the virus in the body without causing kidney damage, which is a common side effect of similar treatments. ^{1 2 3 4 5}

Is Brincidofovir safe for human use?

Brincidofovir (also known as CMX001) has been used successfully in patients with severe adenovirus infections, including those who are immunocompromised, with reports indicating it is generally safe and well-tolerated. It is noted for having limited toxicity compared to similar treatments and does not cause kidney damage, which is a concern with some other antiviral drugs. ^{1 2 5 6 7}

How is the drug Brincidofovir different from other treatments for adenovirus infections?

Brincidofovir is unique because it is an oral drug that is a lipid-conjugated form of cidofovir, offering higher levels of the active drug inside cells without the kidney toxicity associated with intravenous cidofovir. It is particularly useful for patients who cannot tolerate other treatments due to kidney issues. ^{1 2 3 6 8}

What is the purpose of this trial?

The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV

Eligibility Criteria

This trial is for individuals aged 2 months and older with Adenovirus infection, showing high virus levels in the blood. Participants must either have a widespread infection or be immunocompromised with asymptomatic or localized disease. They should need intravenous treatment but can't join if they have severe skin reactions, gut/liver issues from graft-versus-host disease, weigh over 120 kg, or had recent severe diarrhea.

Inclusion Criteria

AdV DNA viremia >10,000 copies/mL from a single sample, or 2 samples greater than 48 hours apart with the second result higher than the first and both greater than 1000 copies/mL, from the data obtained from the designated central virology laboratory of the local laboratory using the blood sample(s) collected informed consent has been obtained and within 7 days prior to Day 1 (AdV DNA viremia results collected within the 7 day window, but prior to consent may be used if the Informed Consent Form (ICF) signed by the subject provides approval).

Male or female, aged 2 months and older at the time of informed consent.

Either (a) have disseminated AdV disease or (b) have an underlying immunocompromised state, and have asymptomatic AdV infection or localized AdV disease.

Exclusion Criteria

NIH Stage 4 acute GVHD of the skin (i.e., generalized erythroderma with bullous formation) within 7 days prior to Day 1.

NIH Stage 2 or higher acute GVHD of the gut (i.e., diarrhea >556 mL/m2/day for pediatric subjects [or >1000 mL/day for young adults as applicable, at centers in the United States only], or severe abdominal pain with or without ileus) within 7 days prior to Day 1.

Subjects who weigh ≥120 kg.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive intravenous Brincidofovir (BCV) at varying doses for 4 weeks

4 weeks

8 visits (in-person) for BIW dosing, 4 visits (in-person) for QW dosing

Follow-up

Participants are monitored for safety and effectiveness after treatment

15 weeks

Weekly monitoring

Treatment Details

Interventions

• Brincidofovir

Trial Overview The study tests different doses of an intravenous drug called Brincidofovir (BCV) to find a safe and tolerable amount for treating Adenovirus infections. It's given in increasing amounts to see how patients handle it.

Participant Groups

Group I: BCV 0.4 mg/kg QW Experimental Treatment 1 Intervention

BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours

Group II: BCV 0.4 mg/kg BIW Experimental Treatment 1 Intervention

BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours

Group III: BCV 0.3mg/kg BIW Experimental Treatment 1 Intervention

BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours

Group IV: BCV 0.2mg/kg BIW Experimental Treatment 1 Intervention

BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours

Brincidofovir is already approved in United States for the following indications:

Approved in United States as Tembexa for:

• Smallpox disease caused by variola virus

Who Is Running the Clinical Trial?

SymBio Pharmaceuticals

Lead Sponsor

Trials

24

Recruited

740+

Founded

2005

Headquarters

Tokyo, Japan

Known For

Rare disease research

Top Products

brincidofovir, bendamustine liquid formulation, rigosertib sodium

Findings from Research

Brincidofovir (CMX001) is an effective oral treatment for severe adenoviral pneumonia in renal transplant recipients, especially when intravenous cidofovir causes renal insufficiency.

Brincidofovir has advantages over cidofovir, including better oral bioavailability, no nephrotoxicity, and higher levels of the active drug, making it a safer option for treating adenovirus infections in transplant patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Brincidofovir (CMX001) for the Treatment of Severe Adenoviral Pneumonia in Kidney Transplant Recipient. Sudhindra, P., Knoll, B., Nog, R., et al.[2020]

Brincidofovir (BCV) has shown promise as a treatment for disseminated adenovirus infections (d-ADV) in pediatric patients after hematopoietic cell transplant (HCT), which are often fatal and have limited treatment options.

In a report involving four pediatric HCT recipients, all were successfully treated with BCV, indicating its potential efficacy in managing this serious infection.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection. Chan, SY., Prockop, SE., Boulad, F., et al.[2021]

Brincidofovir (BCV) demonstrated antiviral activity against adenoviruses in immunocompromised patients, with 67% of subjects on the BCV twice weekly regimen achieving undetectable adenovirus viremia after one week, compared to only 29% in the once weekly group and 33% in the placebo group.

While BCV treatment showed a trend towards lower all-cause mortality compared to placebo, it was associated with a higher incidence of diarrhea and acute graft-versus-host disease, indicating the need for careful monitoring of side effects in patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. Grimley, MS., Chemaly, RF., Englund, JA., et al.[2020]

Brincidofovir, a new oral treatment for adenovirus infections, shows promise in being safe and effective in reducing adenovirus levels and related complications in immunosuppressed patients, particularly those undergoing hematopoietic stem cell transplants, as indicated by preliminary results from a phase III clinical trial.

Unlike its predecessor cidofovir, brincidofovir has better cellular uptake and does not cause kidney damage, making it a significant advancement in the treatment of adenovirus infections.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New drug on the horizon for treating adenovirus. Wold, WS., Toth, K.[2020]

Brincidofovir (BCV) was successfully used to treat a 9-year-old girl with disseminated adenovirus infection after hematopoietic stem cell transplantation, demonstrating its potential as an effective antiviral therapy in immunocompromised patients.

Compared to standard antiviral treatments like Cidofovir, Brincidofovir offers increased efficacy against various viral infections, has a better safety profile with limited toxicity, and can be administered orally, making it more accessible in different healthcare settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation. Van Genechten, T., van Heerden, J., Bauters, T., et al.[2020]

In a study of 8 pediatric HSCT recipients with refractory adenovirus infections, 75% experienced complete resolution of AdV DNAemia and intestinal infections after treatment with brincidofovir (BCV).

High levels of AdV DNAemia (over 1 × 10^9/mL) and poor lymphocyte recovery were linked to increased mortality, but early AdV DNAemia did not worsen outcomes, indicating that BCV may be a promising option for managing AdV infections in immunocompromised patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of Brincidofovir in Pediatric Stem Cell Transplant Recipients With Adenovirus Infections. Ehlert, K., Schulte, JH., Kühl, JS., et al.[2021]

CMX001 (Brincidofovir) is an orally bioavailable antiviral that is converted inside cells to its active form, cidofovir diphosphate, enhancing its effectiveness against double-stranded DNA viruses.

The lipid conjugation of CMX001 allows for higher concentrations of the active drug within cells while maintaining lower levels in the bloodstream, which may improve safety and reduce potential side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Florescu, DF., Keck, MA.[2022]

Brincidofovir (BCV) demonstrated effective anti-adenoviral activity in five pediatric patients with adenovirus infections following hematopoietic stem cell transplantation, showing a good safety profile without nephrotoxicity.

All patients treated with BCV responded well, with a median time of 30 days to achieve negative adenoviremia, suggesting BCV could be a valuable option for preemptive therapy in this high-risk population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Brincidofovir as a Salvage Therapy in Controlling Adenoviremia in Pediatric Recipients of Hematopoietic Stem Cell Transplant. Meena, JP., Phillips, RS., Kinsey, S.[2023]

References

1. United States pubmed.ncbi.nlm.nih.gov

Brincidofovir (CMX001) for the Treatment of Severe Adenoviral Pneumonia in Kidney Transplant Recipient. [2020]

2. Korea (South) pubmed.ncbi.nlm.nih.gov

Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection. [2021]

3. United States pubmed.ncbi.nlm.nih.gov

Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. [2020]

4. England pubmed.ncbi.nlm.nih.gov

New drug on the horizon for treating adenovirus. [2020]

5. Egypt pubmed.ncbi.nlm.nih.gov

Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation. [2020]

6. England pubmed.ncbi.nlm.nih.gov

Efficacy of Brincidofovir in Pediatric Stem Cell Transplant Recipients With Adenovirus Infections. [2021]

7. England pubmed.ncbi.nlm.nih.gov

Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. [2022]

8. United States pubmed.ncbi.nlm.nih.gov

Brincidofovir as a Salvage Therapy in Controlling Adenoviremia in Pediatric Recipients of Hematopoietic Stem Cell Transplant. [2023]